News: Novartis AG (NVS.N)

NVS.N on New York Stock Exchange

88.60USD
4:00pm EDT
Price Change (% chg)

$-0.03 (-0.03%)
Prev Close
$88.63
Open
$88.45
Day's High
$88.94
Day's Low
$88.34
Volume
142,428
Avg. Vol
232,432
52-wk High
$91.65
52-wk Low
$72.24

Search Stocks
Select another date:

Deals of the day- Mergers and acquisitions

Aug 20 - The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Wednesday:

Novartis hands over experimental TB drugs in antibiotic pullback

ZURICH - Novartis has signed a licensing deal to hand over its experimental tuberculosis (TB) drugs to the Global Alliance for TB Drug Development, joining a growing Big Pharma retreat from antibiotics.

UPDATE 1-Novartis hands over experimental TB drugs in antibiotic pullback

* Novartis move adds to Big Pharma retreat from antibiotics R&D (Adds detail, analyst, Novartis comment)

Novartis licenses experimental tuberculosis drugs to TB Alliance

ZURICH, Aug 20 - Novartis said on Wednesday it had signed an a deal to exclusively license its experimental drugs for tuberculosis (TB) to the Global Alliance for TB Drug Development.

Novartis to invest in Israel's Gamida Cell, could buy out company

JERUSALEM - Swiss drugmaker Novartis has agreed to take a 15 percent stake in Gamida Cell, an Israeli developer of stem cell therapies, in a deal that could reach more than $600 million, Gamida's parent said on Tuesday.

Novartis to invest in Israel's Gamida Cell, could buy out company

JERUSALEM, Aug 19 - Swiss drugmaker Novartis has agreed to take a 15 percent stake in Gamida Cell, an Israeli developer of stem cell therapies, in a deal that could reach more than $600 million, Gamida's parent said on Tuesday.

BRIEF-Novartis to showcase heart failure leadership at ESC congress with results on LCZ696

Aug 11 - Novartis AG : * Says to showcase heart failure leadership at ESC congress 2014 with

Novartis loses new bid to dismiss U.S. lawsuit over kickbacks

NEW YORK - A Manhattan federal judge on Thursday said the U.S. Department of Justice may pursue most of its lawsuit accusing Novartis AG of civil fraud for allegedly using kickbacks to boost sales of drugs covered by Medicare and Medicaid.

RPT-UPDATE 1-Novartis loses new bid to dismiss U.S. lawsuit over kickbacks

NEW YORK, - A Manhattan federal judge on Thursday said the U.S. Department of Justice may pursue most of its lawsuit accusing Novartis AG of civil fraud for allegedly using kickbacks to boost sales of drugs covered by Medicare and Medicaid.

UPDATE 1-Novartis loses new bid to dismiss U.S. lawsuit over kickbacks

NEW YORK, - A Manhattan federal judge on Thursday said the U.S. Department of Justice may pursue most of its lawsuit accusing Novartis AG of civil fraud for allegedly using kickbacks to boost sales of drugs covered by Medicare and Medicaid.

Select another date:
Search Stocks